UK MHRA OKs Allergan's Botox agent
US pharmaceutical and health care firm Allergan says that its wrinkle-reducing product Vistabel (botulinum toxin type A) has been granted a licence in the UK by the Medicines and Healthcare products Regulatory Agency.
The agent may now be used for the temporary improvement in the appearance of moderate-to-severe, between the brow vertical frown lines in those aged 65 and younger, when the severity of the lines has a psychological impact for the patient.
Vistabel is the first and only brand of botulinum toxin type A licensed for cosmetic use in the UK. Allergan noted that glabellar lines are formed by repeated and involuntary contraction of the two major muscles that control movement between the brows, the corrugator and procerus muscles. Over time, the skin becomes less elastic so repeated frowning may cause visible, deep wrinkles between the brows, even when the face is relaxed, the firm added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze